v3.25.1
LOSS PER SHARE
3 Months Ended
Mar. 31, 2025
Loss per share:  
LOSS PER SHARE

NOTE 9— LOSS PER SHARE

 

The following table sets forth the computation of basic and diluted loss per share:

        
  

Three Months Ended

March 31,

 
   2025   2024 
Numerator        
Net loss  $(2,329,062)  $(326,767)
Change in fair value of convertible notes payable         (25,000)
Interest expense         9,863 
Numerator for diluted loss per share  $(2,329,062)  $(341,904)
           
Denominator          
Denominator for basic EPS - weighted-average shares   11,162,026    9,238,913 
Effect of dilutive securities:          
Convertible notes payable         63,938 
Denominator for diluted EPS - adjusted weighted-average shares   11,162,026    9,302,851 
           
Basic loss per share  $(0.21)  $(0.04)
Diluted loss per share  $(0.21)  $(0.04)

 

Basic (loss) earnings per share is computed by dividing income or loss attributable to the shareholders of common stock (the numerator) by the weighted-average number of shares of common stock outstanding (the denominator) for the period. Diluted (loss) earnings per share assume that any dilutive equity instruments, such as convertible notes payable and warrants were exercised and outstanding common stock adjusted accordingly, if their effect is dilutive.

 

The Company’s convertible note payable at fair value, the warrant and the Series C preferred stock have clauses that entitle the holder to participate if dividends are declared to the common stockholders as if the instruments had been converted into shares of common stock. As such, the Company uses the two-class method to compute earnings per share and attribute a portion of the Company’s net income to these participating securities. These securities do not contractually participate in losses. For the three months ended March 31, 2025 and 2024, the Company had a net loss and as such the two-class method is not presented.

 

For the three months ended March 31, 2025, potentially dilutive instruments including 5,234,064 shares of common stock issuable upon conversion of convertible notes outstanding and 10,000 shares of common stock issuable upon exercise of the Series I Warrant were not included in the diluted loss per share as inclusion was considered to be antidilutive.

 

For the three months ended March 31, 2024, potentially dilutive instruments including 1,790,607 shares of common stock upon conversion of convertible notes outstanding and 10,000 shares of common stock issuable upon exercise of the Series I Warrant were not included in the diluted loss per share as inclusion was considered to be antidilutive.